Is antisense gene therapy a step in the right direction in the control of hypertension?

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 277, Issue 2 46-2, 1999, Pages

  Raizada, Mohan K ^b   Katovich, Michael J ^b   Wang, Hongwei ^b   Berecek, Kathleen H ^a   Gelband, Craig H ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; ATRIAL NATRIURETIC FACTOR; CALCIUM ION; COMPLEMENTARY DNA; COMPLEMENTARY RNA; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; KALLIKREIN; LOSARTAN; MESSENGER RNA; NITRIC OXIDE SYNTHASE; PHENYLEPHRINE; RENIN;

ADENO ASSOCIATED VIRUS; CLONING VECTOR; EDITORIAL; GENE TARGETING; GENE TECHNOLOGY; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HYPERTENSION; INTRACARDIAC DRUG ADMINISTRATION; NONHUMAN; NUCLEIC ACID PROBE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; VIRUS RECOMBINANT;

EID: 0032869180     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.1999.277.2.h423     Document Type: Editorial

References (54)

1. Borghi, C., and E. Anbrosioni. Evidence-based medicine and ACE inhibition. J. Cardiovasc. Pharmacol. 2, Suppl. 2: S24-S35, 1998.
2. Channon, K. M., and S. E. George. Improved adenoviral vectors: cautious optimism for gene therapy. Quart. J. Med. 90: 105-109, 1997.
3. Chao, J., J. J. Zhang, K. F. Lin, and L. Chao. Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. Hum. Gene Ther. 9: 21-31, 1998.
4. DeGasparo, M., and N. Levens. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme? Pharmacol. Toxicol. 82: 257-271, 1998.
5. Dzau, V. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch. Intern. Med. 153: 937-942, 1993.
6. Flotte, T. R., and B. J. Carter. Adeno-associated virus vectors for gene therapy. Gene Ther. 2: 357-362, 1995.
7. Gelband, C. H., M. J. Katovich, and M. K. Raizada. Antisense gene therapy in the long-term control of hypertension. Gene Ther. Mol. Biol. 3: 1-8, 1998.
8. 1R-AS) in the adult spontaneously hypertensive rat (SHR) (Abstract). Circulation 98: I-320, 1998.
9. Gelband, C. H., P. Y. Reaves, J. Evans, H.-W. Wang, M. J. Katovich, and M. K. Raizada. Angiotensin II type 1 receptor antisense gene therapy prevents altered renal vascular calcium homeostasis in hypertension. Hypertension 33: 360-365, 1999.
10. Gibbons, G. H. Cardioprotective mechanisms of ACE inhibition. The angiotensin II-nitric oxide balance. Drugs 54, Suppl. 5: 1-11, 1997.
11. Griendling, K. K., and R. W. Alexander. Endothelial control of the cardiovascular system: recent advances. FASEB J. 10: 283-292, 1996.
12. Griendling, K. K., and R. W. Alexander. Oxidative stress and cardiovascular disease. Circulation 96: 3264-3265, 1997.
13. Guntaka, R. V., and S. K. Swamynathan. Retroviral vectors for gene therapy. Indian J. Exp. Biol. 36: 539-545, 1998.
14. Hallek, M., and C. M. Wendtener. Recombinant adeno-associated virus (rAAV) vectors for somatic gene therapy; recent advances and potential clinical applications. Cytokines Mol. Ther. 2: 69-79, 1996.
15. Harris, J. D., and N. R. Lamina. Strategies for targeted gene therapy. Trends Genet. 12: 400-405, 1996.
16. Hornig, B., N. Arakawa, and H. Drexler. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Eur. Heart J. 19, Suppl. G: G48-G53, 1998.
17. Howes, L. G., and N. Christie. Angiotensin receptor antagonists and ACE inhibitors. Aust. Fam. Physician 27: 914-921, 1998.
18. Iyer, S. N., D. Lu, M. J. Katovich, and M. K. Raizada. Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense. Proc. Natl. Acad. Sci. USA 93: 9960-9965, 1996.
19. Johnston, C. I., M. Naitoh, and L. M. Burrell. Rationale and pharmacology of angiotensin II receptor antagonists: current status and future issues. J. Hypertension 15, Suppl.: S3-S6, 1997.
20. Kang, P. M., A. J. Landau, R. T. Eberhardt, and W. H. Fishman. Angiotensin II receptor antagonists: a new approach to blockade of the renin angiotensin system. Am. Heart J. 127: 1388-1401, 1994.
21. Kovesidi, I., D. E. Brough, J. T. Bruder, and T. J. Wickham. Adenoviral vectors for gene transfer. Curr. Opin. Biotechnol. 8: 583-589, 1997.
22. Langer, J. C., M. E. Klotman, B. Hanss, N. Tulchin, L. A. Bruggeman, P. E. Klotman, and M. S. Lipkowitz. Adeno-associated virus gene transfer into renal cells: potential for in vivo gene delivery. Exp. Nephrol. 6:189-194, 1998.
23. Lee, R. J., and L. Huang. Lipidic vector systems for gene therapy. Crit. Rev. Ther. Drug Carrier Syst. 14:173-206, 1999.
24. Lin, K. F., J. Chao, and L. Chao. Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in salt-sensitive rats. Hum. Gene Ther. 9: 1429-1438, 1998.
25. Lin, K. F., J. Chao, and L. Chao. Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension 26: 847-853, 1995.
26. Lu, D., and M. K. Raizada. Delivery of angiotensin II type 1 receptor antisense inhibits angiotensin action in neurons from hypertensive rat brain. Proc. Natl. Acad. Sci. USA 92: 2914-2918, 1995.
27. Lu, D., M. K. Raizada, S. Iyer, P. Reaves, H. Yang, and M. J. Katovich. Losartan versus gene therapy chronic control of high blood pressure in spontaneously hypertensive rats. Hypertension 30: 363-370, 1997.
28. 1 receptor antisense in neurons and SMC. Am. J. Physiol. 274 (Heart Circ. Physiol. 43): H719-H727, 1998.
29. 1 RS and angiotensin action in astroglia and neuronal cells in primary culture. Proc. Natl. Acad. Sci. USA 92: 1162-1166, 1995.
30. Makino, N., M. Sugano, S. Ohtsuka, and S. Sawada. Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats. Hypertension 31: 1166-1170, 1998.
31. Martens, J. R., P. Y. Reaves, D. Lu, K. H. Berecek, S. P. Bishop, M. J. Katovich, M. K. Raizada, and C. H. Gelband. Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy. Proc. Natl. Acad. Sci. USA 95: 2264-2669, 1998.
32. McKeen, T. D., M. E. De Rome, G. Y. Wu, and M. A. Findeis. Preparation of asialoorosomucoid-polylysine conjugates. Bioconjug. Chem. 5: 306-311, 1994.
33. Middleton, P. G., and E. W. Alton. Gene therapy for cystic fibrosis: which postman, which box? Thorax 53: 197-199, 1998.
34. Mombouli, J. V. ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide. Drugs 54, Suppl. 5: 12-22, 1997.
35. 2T binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci. USA 92: 5855-5859, 1995.
36. Morishita, R., G. H. Gibbons, K. E. Ellison, M. Nakajima, L. Zhang, Y. Kaneda, T. Ogihara, and V. J. Dzau. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides. Proc. Natl. Acad. Sci. USA 90: 8474-8478, 1993.
37. Naldini, L., U. Blomer, F. H. Gage, D. Trono, and I. M. Verma. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. USA 93: 11382-11388, 1996.
38. Parmley, W. W. Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection. Am. J. Med. 105: 27S-31S, 1998.
39. 1 receptor mRNA in brain and blood. Hypertension 31: 1317-1323, 1998.
40. 1R mRNA antisense. Hypertension 29: 374-380, 1997.
41. Pitt, B. Regression of left ventricular hypertrophy in patients with hypertension: blockade of the renin-angiotensin-aldosterone system. Circulation 98: 1987-1989, 1998.
42. Raizada, M. K., D. Lu, H. Yang, E. M. Richards, C. H. Gelband, and C. Sumners. Brain angiotensin receptor subtypes and their coupling to distinct signal pathways. In: Advanced Molecular Cellular Endocrinology, edited by D. Le Roith. Stamford, CT: JAI, 1999, vol. 3, p. 75-101.
43. Regan, C. P., S. P. Bishop, and K. H. Berecek. Early, short-term treatment with captopril permanently attenuates cardiovascular changes in spontaneously hypertensive rats. Clin. Exp. Hypertens. 19: 1161-1177, 1997.
44. Robbins, P. D., and S. C. Ghivizzani. Viral vectors for gene therapy. Pharmacol. Ther. 80: 35-47, 1998.
45. Romano, G., P. P. Claudio, H. E. Kaiser, and A. Giordano. Recent advances, prospects, and problems in designing new strategies for oligonucleotide and gene delivery in therapy. In Vivo 12: 59-67, 1998.
46. Stamler J., R. Stamler, and J. D. Neaton. Blood pressure, systolic and diastolic, and cardiovascular risks. CLS population data. Arch. Intern. Med. 153: 598-615, 1993.
47. Tomita, N., J. Higaki, Y. Kaneda, H. Yu, R. Morishita, H. Mikami, and T. Ogihara. Hypertensive rats produced by in vivo introduction of the human renin gene. Circ. Res. 73: 898-905, 1993.
48. Tomita N., R. Morishita, J. Higaki, M. Aoki, Y. Nakamura, H. Mikami, A. Fukamizu, K. Murakami, Y. Kaneda, and T. Ogihara. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen. Hypertension 26: 131-136, 1995.
49. Vaughan, D. F. Fibrinolytic balance, the renin-angiotensin system and atherosclerotic disease. Eur. Heart J. 19, Suppl. G: G9-G12, 1998.
50. Vaughan, D. E., J. L. Rouleau, P. M. Ridker, J. M. Arnold, F. J. Menapace, and M. A. Pfeffer. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infraction. HEART Study Investigators. Circulation 96: 442-447, 1997.
51. Verma, I. M., and N. Somia. Gene therapy: promises, problems, and prospects. Nature 389: 239-242, 1997.
52. 1R) antisense in vitro and in vivo. Methods in Enzymology: Antisense Techniques. In press.
53. Whelton, P. K. Epidemiology of hypertension. Lancet 334: 101-106, 1994.
54. Wivel, N. A., and J. M. Wilson. Methods of gene delivery. Hematol. Oncol. Clin. North Am. 12: 483-501, 1998.